论文部分内容阅读
目的探讨依达拉奉联合硫辛酸治疗急性缺血性卒中的临床疗效。方法 76例急性缺血性卒中患者随机分为试验组和对照组,各38例。在均使用阿司匹林和阿托伐他汀的基础上,对照组予以依达拉奉静脉滴注,试验组则予以依达拉奉和硫辛酸静脉滴注。治疗2周后,对两组患者进行美国国立卫生研究院卒中量表(NIHSS)评分,比较两组的评分差异。结果治疗后,两组患者NIHSS评分均有所改善,且试验组的改善优于对照组(P<0.05)。结论依达拉奉联合硫辛酸治疗较单纯依达拉奉治疗能改善急性缺血性卒中患者的事件功能缺损。
Objective To investigate the clinical efficacy of edaravone combined with lipoic acid in the treatment of acute ischemic stroke. Methods 76 patients with acute ischemic stroke were randomly divided into experimental group and control group, 38 cases in each. On the basis of both aspirin and atorvastatin, the control group was given intravenous infusion of edaravone, and the experimental group was given intravenous infusion of edaravone and lipoic acid. After 2 weeks of treatment, NIH Stroke Scale (NIHSS) scores were compared between the two groups, and the differences between the two groups were compared. Results After treatment, the NIHSS scores of both groups were improved, and the improvement of the experimental group was better than that of the control group (P <0.05). Conclusion Edaravone combined with lipoic acid can improve the functional impairment of patients with acute ischemic stroke when treated with edaravone alone.